NCT01974856View on ClinicalTrials.gov

A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay

CompletedOBSERVATIONAL
Enrollment

201

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

June 30, 2015

Conditions
Breast Cancer
Trial Locations (2)

24105

Universitätsklinikum Kiel, Kiel

89081

Universitätsfrauenklinik Ulm, Ulm

Sponsors
All Listed Sponsors
lead

NanoString Technologies, Inc.

INDUSTRY

NCT01974856 - A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay | Biotech Hunter | Biotech Hunter